ОБ ЭТОМ ЭПИЗОДЕ
Could you have metabolic dysfunction even at a normal weight?
This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone.
KEY TAKEAWAYS
Weight and metabolic health are not the same thing - you can be metabolically unhealthy at any size
Normal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providers
Key screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRP
Metabolic dysfunction can start in your 20s and take decades to develop into serious disease
Both normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weight
Early screening and treatment can prevent catastrophic health outcomes later in life
The liver plays a crucial role in metabolism and can become insulin resistant regardless of body weight
NOTABLE QUOTE
"You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Appendix: Key References
Primary literature supporting this episode
• Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023.
• Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025.
• Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024.
• Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity.
• International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes.
Mechanism references
• MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023.
• Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship.
• Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026.
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
